- Home
- VCIG vs CVKD Comparison
VCIG vs CVKD Comparison
Compare VCIG & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIG
- CVKD
- Stock Information
- Founded
- VCIG 2013
- CVKD 2022
- Country
- VCIG Malaysia
- CVKD United States
- Employees
- VCIG N/A
- CVKD N/A
- Industry
- VCIG Diversified Commercial Services
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- VCIG Consumer Discretionary
- CVKD Health Care
- Exchange
- VCIG Nasdaq
- CVKD Nasdaq
- Market Cap
- VCIG 22.5M
- CVKD 27.0M
- IPO Year
- VCIG 2023
- CVKD 2023
- Fundamental
- Price
- VCIG $2.55
- CVKD $13.21
- Analyst Decision
- VCIG
- CVKD Strong Buy
- Analyst Count
- VCIG 0
- CVKD 1
- Target Price
- VCIG N/A
- CVKD $32.00
- AVG Volume (30 Days)
- VCIG 654.9K
- CVKD 28.4K
- Earning Date
- VCIG 10-06-2025
- CVKD 11-06-2025
- Dividend Yield
- VCIG N/A
- CVKD N/A
- EPS Growth
- VCIG N/A
- CVKD N/A
- EPS
- VCIG 270.67
- CVKD N/A
- Revenue
- VCIG $32,903,041.00
- CVKD N/A
- Revenue This Year
- VCIG N/A
- CVKD N/A
- Revenue Next Year
- VCIG N/A
- CVKD N/A
- P/E Ratio
- VCIG $0.01
- CVKD N/A
- Revenue Growth
- VCIG 24.77
- CVKD N/A
- 52 Week Low
- VCIG $2.54
- CVKD $8.74
- 52 Week High
- VCIG $4,644.00
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- VCIG 34.69
- CVKD 42.81
- Support Level
- VCIG $3.10
- CVKD $13.51
- Resistance Level
- VCIG $4.60
- CVKD $14.35
- Average True Range (ATR)
- VCIG 0.66
- CVKD 0.53
- MACD
- VCIG -0.49
- CVKD -0.16
- Stochastic Oscillator
- VCIG 0.00
- CVKD 19.67
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.